Journal of controlled release : official journal of the Controlled Release Society

Design of messenger RNA vaccines using mixed fat and polymer nanoparticles

Updated

Abstract

Lipid-polymer hybrid nanoparticles (LPNs) loaded with mRNA produced higher spike-specific IgG responses and reduced SARS-CoV-2 load in the nasal cavity compared to traditional lipid nanoparticles (LNPs).

  • The design of LPNs incorporates a biocompatible polymer, ionizable lipid, and helper lipid, allowing for effective mRNA delivery.
  • Key factors influencing mRNA delivery include total lipid content and the ionizable lipid:mRNA weight ratio.
  • LPNs demonstrated localized protein expression at the injection site, unlike traditional LNPs which expressed protein in the liver.
  • Lower flow rate ratios during formulation resulted in a polymer core-shell hybrid structure, while higher ratios led to a mix of multi-lamellar vesicles and nanospheres.
  • In mouse models, LPNs elicited CD8 T-cell and antibody responses comparable to those from LNPs.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest AL, AT, SB, HF, and CF are listed as co-inventors on a patent application covering the use of LPNs. DC and GKP are employed by Statens Serum Institut, a non-profit government research facility. Dennis Christensen is an employee of Croda Denmark. CF consults for Lonza and Sanofi. The other authors have no financial conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free